Takeda partners with Tri-I TDI

The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) announced that it has reached an expansion agreement with Takeda Pharmaceutical Company Ltd. this week.
  
Through this expansion the relationship between research and academic institutions and the industry will be strengthened. The CEO of the Memorial Sloan Kettering Cancer Center, Dr. Craig Thompson, said this will also have a large role in shaping medical research.

The Tri-I TDI consists of Memorial Sloan Kettering, Weill Cornell Medicine and the Rockefeller University.

The collaborative efforts of the institutes are focused on the development of diagnostic and therapeutic agents and to connect this with early research stages that take place at academic institutions.

Thompson also stated that efficient research pathways lead to eventual drug commercialization through the Tri-I TDI. Takeda is the sole industry partner for the collaborative body.

“As we look ahead to what’s next, beyond small molecule drug discovery, this flagship collaboration will continue to push the boundaries of what’s possible in medical research,” Takeda’s Chief Medical and Scientific Officer Andrew Plump said. “We at Takeda understand the value of, and connection between, innovation and external collaboration. This is why we are so pleased to continue our relationship with the Tri-I TDI and help expand its mission to move toward novel research frontiers such as antibody drug discovery.”